Drugs / Polypodium leucotomos extract
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02813902 Comparator | Jul 2019 → May 2020 | actinic keratosis, keratosis | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polypodium leucotomos extract | “Polypodium leucotomos extract capsules” NCT02813902 ↗ |
| Route | Oral | “240 mg taken orally daily over the course of 1 year” NCT02813902 ↗ |